MedTrace Logo

Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System

NCT05437679 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2023-09-05

No results posted yet for this study

Summary

This study is designed to evaluate the presence and numbers of circulating tumor cells (CTCs) and cancer related gene expression levels in subjects with localized high-risk prostate cancer (HRLPC) and from subjects with non-metastatic disease experiencing biochemical recurrence and castration-resistance (BCRLPC and NMCRPC groups, respectively) who are about to undergo next generation imaging (NGI, such as Axumin® or PSMA PETCT). The investigators will also evaluate subjects with localized indolent prostate cancer who are on active surveillance (AS) as a control population. The CTC and gene expression results will be evaluated for association with disease state and progression and survival.

Conditions

  • High Risk Prostate Carcinoma
  • Biochemically Recurrent Prostate Carcinoma
  • Castration-resistant Prostate Cancer
  • Prostate Cancer

Interventions

OTHER

Blood collection

Peripheral blood will be collected from each subject at a single time point and data will be collected from a review of each subject's medical records.

Sponsors & Collaborators

  • MidLantic Urology, LLC

    collaborator UNKNOWN

  • Angle plc

    lead INDUSTRY

Principal Investigators

  • Jose G Moreno, MD · MidLantic Urology, LLC

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-05
Primary Completion
2023-08-22
Completion
2023-08-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05437679 on ClinicalTrials.gov